Cargando…
Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
Autores principales: | Heery, Christopher R, Donahue, Renee, Lepone, Lauren, Grenga, Italia, Richards, Jacob, Metenou, Simon, Fernando, Romaine I, Dirmeier, Ulrike, Singh, Harpreet, Madan, Ravi, Gulley, James L, Schlom, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645490/ http://dx.doi.org/10.1186/2051-1426-3-S2-P132 |
Ejemplares similares
-
Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014) -
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021) -
MVA-brachyury Tricom vaccine/pembrolizumab: Various toxicities: case report
Publicado: (2021) -
Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013) -
Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)